公开(公告)号：US20080132464A1

公开(公告)日：2008-06-05

申请号：US11938562

申请日：2007-11-12

申请人： Peter A. Campochiaro ,  Peter Gehlbach

发明人： Peter A. Campochiaro ,  Peter Gehlbach

IPC分类号： A61K31/7052 ,  A61P27/02

CPC分类号： A61K31/7052 ,  A61K38/185 ,  A61K38/57 ,  A61K48/005 ,  C12N15/86 ,  C12N2710/10343

摘要： The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.

摘要翻译： 本发明涉及一种预防性或治疗性地治疗脉络膜新生血管形成的方法，其中该方法包括直接向眼睛施用治疗因子或编码治疗因子的核酸序列，所述治疗因子或核酸序列表达以产生治疗因子，以选择诱导 与脉络膜新生血管形成相关的内皮细胞的凋亡，使得脉络膜新生血管形成被预防性或治疗性地治疗。 本发明还提供了预防性或治疗性治疗眼新生血管形成的方法，其中所述方法包括直接向眼睛施用编码治疗因子的核酸序列，以促进与新血管形成相关的内皮细胞的凋亡，使得所述核酸由此产生 预防或治疗眼部新生血管形成的治疗因素。

公开(公告)号：US07989426B2

公开(公告)日：2011-08-02

申请号：US11938562

申请日：2007-11-12

申请人： Peter A. Campochiaro ,  Peter Gehlbach

发明人： Peter A. Campochiaro ,  Peter Gehlbach

IPC分类号： A61K48/00 ,  A01N63/00

CPC分类号： A61K31/7052 ,  A61K38/185 ,  A61K38/57 ,  A61K48/005 ,  C12N15/86 ,  C12N2710/10343

摘要： The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.

摘要翻译： 本发明涉及一种预防性或治疗性地治疗脉络膜新生血管形成的方法，其中该方法包括直接向眼睛施用治疗因子或编码治疗因子的核酸序列，所述治疗因子或核酸序列表达以产生治疗因子，以选择诱导 与脉络膜新生血管形成相关的内皮细胞的凋亡，使得脉络膜新生血管形成被预防性或治疗性地治疗。 本发明还提供了预防性或治疗性治疗眼新生血管形成的方法，其中所述方法包括直接向眼睛施用编码治疗因子的核酸序列，以促进与新血管形成相关的内皮细胞的凋亡，使得所述核酸由此产生 预防或治疗眼部新生血管形成的治疗因素。

公开(公告)号：US06573271B2

公开(公告)日：2003-06-03

申请号：US09954686

申请日：2001-09-11

申请人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

发明人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

IPC分类号： A61K31435

CPC分类号： A61K31/455 ,  A61K31/192 ,  Y10S514/912

摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

公开(公告)号：US07309483B2

公开(公告)日：2007-12-18

申请号：US11073091

申请日：2005-03-04

申请人： Stanley J. Wiegand ,  Peter A. Campochiaro ,  George D. Yancopoulos

发明人： Stanley J. Wiegand ,  Peter A. Campochiaro ,  George D. Yancopoulos

IPC分类号： A61K38/19

CPC分类号： A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/0306 ,  A61K38/00 ,  C07K14/515

摘要： The invention provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

摘要翻译： 本发明提供治疗组合物以及阻断血管生长的方法，促进新血管形成的方法，促进表达TIE-2受体的细胞的生长或分化的方法，阻止生长或分化的方法 表达TIE-2受体的细胞和减弱或预防人类肿瘤生长的方法。

公开(公告)号：US6075032A

公开(公告)日：2000-06-13

申请号：US875665

申请日：1998-01-23

申请人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

发明人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/19 ,  A61K31/192 ,  A61K31/455 ,  A61K31/465 ,  A61K45/00 ,  A61K47/24 ,  A61P27/02 ,  A61P35/00 ,  A61K31/435 ,  A61K31/07

CPC分类号： A61K31/455 ,  A61K31/192 ,  Y10S514/912

摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

摘要翻译： PCT No.PCT / US96 / 01505 Sec。 371日期1998年1月23日 102（e）日期1998年1月23日PCT提交1996年1月31日PCT公布。 公开号WO96 / 23498 日期1996年8月8日通过使视网膜色素上皮细胞与治疗量的视黄酸接触来预防手术或创伤后视网膜色素上皮细胞增生或与脉络膜新生血管形成相关的眼部疾病，如年龄相关性黄斑变性和组织胞浆菌病综合征 受体（RAR激动剂，优选具有对视黄酸受体具有比活性的激动剂），优选地，RAR激动剂也是AP1依赖性基因表达的有效拮抗剂，或者，用治疗量的AP-1改善视网膜色素上皮的增殖 拮抗剂，单独或与RAR激动剂组合，药物可以通过使用约50至150μg的剂量通过快速注射进入玻璃体腔中，或通过从脂质体缓慢释放或注入玻璃体腔的油栓塞来施用。 还提供了用于防止视网膜色素上皮细胞增殖的制剂。

公开(公告)号：US06479729B1

公开(公告)日：2002-11-12

申请号：US09587184

申请日：2000-06-05

申请人： Peter A. Campochiaro ,  Donald J. Zack

发明人： Peter A. Campochiaro ,  Donald J. Zack

IPC分类号： G01N3300

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  C07K14/52 ,  C12N2830/008 ,  G01N33/5088

摘要： Transgenic mammals are provided which develop neovascularization of the retina, similar to that found in a variety of disease states, including diabetes, age related macular degeneration, retinopathy of prematurity, sickle cell retinopathy. These mammals can be used as test systems to evaluate potential prophylactic and therapeutic regimens. The effect of a regimen on the neovascularization is indicative of its beneficial effect in a disease state which is associated with neovascularization.

摘要翻译： 提供转基因哺乳动物，其发生视网膜的新生血管形成，类似于在各种疾病状态中发现的，包括糖尿病，年龄相关性黄斑变性，早产儿视网膜病变，镰状细胞视网膜病变。 这些哺乳动物可用作测试系统来评估潜在的预防和治疗方案。 方案对新生血管形成的作用表明其与新血管形成相关的疾病状态的有益效果。

公开(公告)号：US5824685A

公开(公告)日：1998-10-20

申请号：US383741

申请日：1995-02-01

申请人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal

发明人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal

IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K31/19 ,  A61K31/192 ,  A61K31/455 ,  A61K31/465 ,  A61K45/00 ,  A61K47/24 ,  A61P27/02 ,  A61P35/00 ,  A61K31/435 ,  A61K31/07

CPC分类号： A61K31/455 ,  A61K31/192 ,  Y10S514/912

摘要： Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epitelium is ameliorated witha therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g, or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

摘要翻译： 通过使视网膜色素上皮细胞与治疗量的视黄酸受体（RAR）激动剂接触，优选对视黄酸受体具有特异性活性的那些激动剂来防止手术或创伤后视网膜色素上皮的增殖。 优选地，RAR激动剂也是AP1依赖性基因表达的有效拮抗剂。 或者，视网膜色素上皮的增殖用治疗量的AP-1拮抗剂单独或与RAR激动剂组合改善。 药物可以通过使用约50至150μg的剂量或通过从注射到玻璃体腔中的脂质体或油栓塞缓慢释放而推注到玻璃体腔中来施用。 还提供了用于防止视网膜色素上皮细胞增殖的制剂。

公开(公告)号：US06372753B1

公开(公告)日：2002-04-16

申请号：US09536221

申请日：2000-03-27

申请人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

发明人： Peter A. Campochiaro ,  Larry A. Wheeler ,  Roshantha A. Chandraratna ,  Sunil Nagpal ,  Eugene De Juan, Jr.

IPC分类号： A61K31435

CPC分类号： A61K31/455 ,  A61K31/192 ,  Y10S514/912

摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

摘要翻译： 通过使视网膜色素上皮细胞与治疗量的视黄酸受体（RAR激动剂，血管内皮细胞生长因子受体）接触，可防止手术或外伤后视网膜色素上皮细胞增生，或导致与脉络膜新生血管形成相关的眼部疾病，如年龄相关性黄斑变性和组织胞浆菌病综合征 优选地，具有比较活性的视黄酸受体，优选地，RAR激动剂也是AP1依赖性基因表达的有效拮抗剂，或者，视网膜色素上皮的增殖用治疗量的AP-1拮抗剂单独或在 与RAR激动剂组合，药物可以通过使用约50至150杯的剂量通过快速注射进入玻璃体腔，或通过从脂质体缓慢释放或注射到玻璃体腔中的油脂填充剂来制备。用于防止视网膜增殖的制剂 还提供了色素上皮。

公开(公告)号：US20120108654A1

公开(公告)日：2012-05-03

申请号：US13002243

申请日：2009-06-30

申请人： Peter A. Campochiaro

发明人： Peter A. Campochiaro

IPC分类号： A61K31/7088 ,  A61P27/02 ,  A61P9/10 ,  A61P39/06 ,  A61P9/04 ,  A61P25/28 ,  A61P3/10 ,  A61P9/00 ,  C12N15/63 ,  A61P25/16

CPC分类号： C12N15/113 ,  A61K9/0048 ,  A61K38/446

摘要： Oxidative damage contributes to cone cell death in retinitis pigmentosa and death of rods, cones, and retinal pigmented epithelial (RPE) cells in ocular oxidative stress related diseases including age-related macular degeneration and retinitis pigmentosa. Oral antioxidants may provide modest benefits, but more efficient ways of preventing oxidative damage are needed. Compositions and methods are provided herein for the prevention, amelioration, and/or treatment of early or late stage ocular disease by increasing the expression or activity of one or more peroxidases in cells of the eye, particularly retinal cells, and further optionally increasing the expression or activity of one or more superoxide dismuatases in the same cells.

摘要翻译： 氧化性损伤导致视网膜色素变性中的锥细胞死亡和眼睛氧化应激相关疾病（包括年龄相关性黄斑变性和色素性视网膜炎）中的棒，锥和视网膜色素上皮（RPE）细胞的死亡。 口服抗氧化剂可能提供适度的益处，但需要更有效的预防氧化损伤的方法。 本文提供了通过增加眼睛细胞，特别是视网膜细胞中一种或多种过氧化物酶的表达或活性来预防，改善和/或治疗早期或晚期眼部疾病的组合物和方法，并进一步任选增加表达 或相同细胞中一种或多种超氧化物歧化酶的活性。

公开(公告)号：US07268137B2

公开(公告)日：2007-09-11

申请号：US10704297

申请日：2003-11-07

申请人： Peter A. Campochiaro

发明人： Peter A. Campochiaro

IPC分类号： A61K31/50

CPC分类号： A61K31/502 ,  A61K31/553 ,  Y10S514/912 ,  A61K2300/00

摘要： A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: wherein n is 0 to 2, R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl; and Z is unsubstituted or substituted pyridyl, an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom, or a salt thereof.

摘要翻译： 公开了一种用于治疗由于视网膜形成引起的视网膜形成或视网膜脱离的受试者的方法。 该方法包括施用下式化合物：其中n为0至2，R为H或低级烷基; X是亚氨基，氧杂或硫杂; Y为芳基; Z为未取代或取代的吡啶基，其N-氧化物，其中1个或更多个N原子携带氧原子，或其盐。